Table 1.
TFI Cox regression: univariate effects and multivariate models.
| Baseline Factors | Risk Factor | HR | p |
|---|---|---|---|
| Clinical Response | no DFI | 1.1 (0.8–1.5) | 0.4821 |
| Year of Diagnosis | per year | 1.0 (1.0–1.0) | 0.7481 |
| Age at Diagnosis | per decade | 0.9 (0.8–1.0) | 0.0946 |
| Stage | IIIC/IV | 1.0 (0.7–1.5) | 0.8200 |
| Grade | 3/4 | 1.9 (1.0–3.5) | 0.0349 |
| Debulking | optimal | 1.3 (1.0–1.7) | 0.0685 |
|
| |||
| Interval-specific factors | Risk level | HR | p |
|
| |||
| Last TFI | per month | 0.9 (0.8–1.0) | 0.0445 |
| Months from Surgery | per month | 1.4 (1.2–1.8) | 0.0003 |
| Recurrences | per previous | 1.1 (1.0–1.3) | 0.0070 |
| 0 vs. 1 | First recurrence | 1.3 (1.1–1.5) | 0.0089 |
| 1 vs. 2 | Second | 1.5 (1.2–1.9) | 0.0009 |
| 2 vs. 3 | Third | 1.4 (1.0–1.9) | 0.0580 |
| 3 vs. 4+ | Later | 0.7 (0.5–1.1) | 0.1500 |
| Platinum treatments | per previous use | 1.4 (1.2–1.6) | 0.0002 |
| Number of Cycles* | Per cycle | 0.8 (0.8–0.9) | <0.0001 |
| Adj. for # Recurrences | Per cycle | 0.9 (0.9–1.0) | 0.1755 |
| Days on Treatment* | Observed/(28 x # Cycles) | 1.0 (0.8–1.4) | 0.8274 |
| Adj. for # Recurrences | Observed/(28 x # Cycles) | 1.1 (0.8–1.4) | 0.7224 |
|
| |||
| Multivariate (Timing Model) | HR | p | |
|
| |||
| Any gemcitabine, taxane, topotecan, doxorubicin or other | 1.7 (1.1–2.5) | 0.0100 | |
| Months from Surgery (log scale) | 1.5 (1.2–1.8) | 0.0001 | |
| Months last TFI (log scale) | 0.9 (0.8–1.0) | 0.0087 | |
| Likelihood ratio test=27.2 on 3 df, p=5.26e-06 | |||
|
| |||
| Multivariate (Regimen Model) | HR | p | |
|
| |||
| Any gemcitabine, taxane, topotecan, doxorubicin or other | 1.7 (1.1–2.5) | 0.0130 | |
| # Previous Regimens | 1.4 (1.2–1.6) | 0.0001 | |
| Likelihood ratio test=22.8 on 2 df, p=1.15e-05 | |||
*
Restricted to cycles (2–8)